Resource needs 2011 – 2015

Contents

1. Executive summary 2
2. The opportunity 3
3. The funding challenge 5
4. Meeting the funding challenge 8
5. Annex 10

Note: The demand estimates described herein are based on the forecast considered by the GAVI Alliance Board in November 2010. An updated forecast will be considered by the Board in July 2011; while estimates for individual components may change, overall demand for 2011-15 is expected to remain close to the previous estimate of US$ 6.8 billion.
1. Executive summary

Every 20 seconds a child dies of a vaccine preventable disease. The GAVI Alliance 2011 pledging conference for immunisation is poised to be a historic moment in advancing the Millennium Development Goals. If fully funded between 2011 and 2015, GAVI Alliance’s support for vaccines will help to immunise nearly 250 million children and save an additional four million lives.

The GAVI Alliance, its donors and partners have the opportunity to accelerate access to cost-effective new vaccines. The expenditure of US$ 6.8 billion needed for 2011-2015 is more than double the amount of the previous five years (2006-2010). This is because of increased demand driven by the opportunity to expand access to new vaccines including those that target the leading causes of childhood mortality: pneumonia and diarrhoea. The vast majority of GAVI’s anticipated expenditures – approximately 85% of programmatic expenditures - for the next five years will be invested in vaccines programmes.

Additional multi-year commitments to GAVI totalling US$ 3.7 billion for 2011-2015 are needed to ensure successful and sustainable long-term programmes in the poorest countries. These long-term commitments will give countries the predictability of funding needed to launch new immunisation programmes, and will give manufacturers the visibility of demand that will shape vaccine markets. Of the US$ 3.7 billion, US$ 1.7 billion is urgently required to finance needs in 2011-2013 and enable the approval of new vaccine applications in 2011.

GAVI is calling on donors to double or triple their commitments to reflect the substantial increase in country demand. Public and private donors are encouraged to invest in GAVI through either direct contributions, and/or GAVI’s innovative financing mechanisms, including the International Finance Facility for Immunisation (IFFIm), and the recently launched Matching Fund for Immunisation (1+1+1).
2. The opportunity

- Every minute, three children die of vaccine preventable diseases.
- Vaccines against pneumonia and diarrhoea, the top two killers of children worldwide, are available but without GAVI support they would remain beyond the grasp of many in the poorest countries.
- The same is true of HPV vaccines that protect women against cervical cancer, and other priority vaccines against diseases including Japanese encephalitis, yellow fever, meningitis, rubella, typhoid, and hepatitis B.

If fully funded over the next five years, the GAVI Alliance’s support for vaccines will help to immunise nearly 250 million children and save an additional four million lives.

US$ 3.7 billion in new funding is needed to meet the US$ 6.8 billion country demand for 2011-2015. The expenditure expected in this period is more than double the amount expended in the last five years (2006-2010). As depicted in the graph below, the 2011-2015 country demand is driven by the opportunity to expand and accelerate the introduction of new vaccines, including pneumococcal and rotavirus.

---

2. The opportunity

- Every minute, three children die of vaccine preventable diseases.
- Vaccines against pneumonia and diarrhoea, the top two killers of children worldwide, are available but without GAVI support they would remain beyond the grasp of many in the poorest countries.
- The same is true of HPV vaccines that protect women against cervical cancer, and other priority vaccines against diseases including Japanese encephalitis, yellow fever, meningitis, rubella, typhoid, and hepatitis B.

If fully funded over the next five years, the GAVI Alliance’s support for vaccines will help to immunise nearly 250 million children and save an additional four million lives.

US$ 3.7 billion in new funding is needed to meet the US$ 6.8 billion country demand for 2011-2015. The expenditure expected in this period is more than double the amount expended in the last five years (2006-2010). As depicted in the graph below, the 2011-2015 country demand is driven by the opportunity to expand and accelerate the introduction of new vaccines, including pneumococcal and rotavirus.

---

2017 Other investment cases “spike” resulted from an investment in Measles Campaign ($147m) and in Polio Stockpile ($191m); both were funded by GAVI bond proceeds.

2 Includes: Health Systems Strengthening (HSS), Civil Society Organisations (CSO) Support, Immunisation Support Services (ISS), Incentives for Routine Immunisation Services (IRS), Injection safety support (INS), and Vaccine Entitlement Grant.
For the 2011-2015 period, GAVI’s direct programmatic support to countries includes vaccines and cash-based support, with vaccines as the bulk of expenditures.

Direct programmatic expenditures 2011-2015 (projected)

as of November 2010

The composition of expenditures is illustrated above, based on demand as projected in November 2010. An updated estimate will be considered by the GAVI Alliance Board in July 2011. At this time, the overall demand for 2011-15 is expected to remain close to the previous (November 2010) estimate of US$ 6.8 billion, with some fluctuations in individual components. Actual demand will evolve in the course of the five-year period. Arising from decisions of the Board in December 2010 regarding the resource envelope and eligibility for cash-based programmes, these programmes are likely to represent a share of programmatic expenditure in the range of 15%-25% in 2011-2015, rather than the 14% previously projected.

Overall expenditures 2011-2015 (projected)
as of November 2010

Direct programmatic expenditures account for 90% of overall expenditures for 2011-2015. A further 10% is for programme implementation activities (mostly through partners such as WHO and UNICEF), and mission support activities of the GAVI Alliance Board and Secretariat.

Annex 1 details the expenditures by commitment level for the period.
### 3. The funding challenge

**US$ 3.7 billion in new funding is needed** to meet the US$ 6.8 billion country demand, in addition to the US$ 3.1 billion that GAVI has already secured in assured funding.

**Assured resources: US$ 3.1 billion**

Of the US$ 3.1 billion in assured resources, US$ 2.8 billion is from existing donor commitments including: direct contributions composed of grants and funding agreements (US$ 0.6 billion); expected proceeds from the Advance Market Commitment (AMC) (US$ 0.8 billion); and expected proceeds from the International Finance Facility for Immunisation (IFFIm) (US$ 1.4 billion).

A further US$ 0.3 billion is available by drawing from GAVI’s cash and investments while still maintaining the GAVI Alliance Board-mandated reserve to cover eight months’ expenditure, and from investment income.
The need for donors to double or triple their contributions to GAVI
Increased country demand is the main driver of GAVI’s funding challenge. As depicted in the graph below, projected country demand (in grey) increases from US$ 1.16 billion in 2011 to US$ 1.37 billion in 2015 and totals US$ 6.8 billion for the entire period 2011-2015, or double the amount of demand for the preceding five years. Of the US$ 6.8 billion, US$ 4.1 billion is for existing programmes and US$ 2.8 billion is for future programmes. Annex 2 provides further details on the projected timing of the country demand.

The second driver of GAVI’s funding challenge is the decreasing of assured resources over the 2011-2015 period. Depicted in the graph below, currently assured resources (in green) decrease from US$ 0.93 billion in 2011 to US$ 0.25 billion in 2015 and totals US$ 3.1 billion for the five-year period. Please see Annex 2 for more details on the timing of the assured resources.

The doubling of country demand combined with the decreasing of assured resources means that contributions in 2011-2015 will need to be at more than double their 2006-2010 level. Hence donors are encouraged to scale-up their contributions accordingly – to double or triple their prior level -- to enable the meeting of increased country demand for vaccines.

Providing predictable funding: the urgent need for 2011-2015 pledges
Donor pledges are crucial to sustaining GAVI’s currently funded programmes and the Alliance’s ability to fund new vaccines. In accordance with GAVI policy, the GAVI Alliance Board cannot approve or endorse new programmes unless sufficient resources exist to cover expenditures projected for the year in which they are approved and the following two calendar years.
Furthermore, many immunisation programmes are long-term. GAVI is committed to continuing to be financially prudent and support sustainable country programmes. In this context, multi-year pledges and commitments help provide countries with the predictability of funding that is essential to launching immunisation programmes.

A core priority to delivering sustainable programmes is to further drive down the prices of vaccines. GAVI’s market shaping activities are greatly enhanced by long-term funding commitments that give manufacturers visibility of future demand.

Immediately following the June 2011 pledging conference the GAVI Alliance Board will make funding decisions on proposals submitted by countries that are recommended by GAVI’s Independent Review Committee (IRC). Of the US$ 3.7 billion needed through 2015, US$ 1.7 billion is urgently required to finance country demand in 2011-2013. Securing this funding in June would enable the Board to approve IRC-recommended proposals, as well as continue existing programmes.

Realising the opportunity: pneumococcal vaccine launches
Thanks to the support of GAVI donors, partners and implementing countries, GAVI has the assured resources needed to launch pneumococcal vaccine in 19 countries over the next five years. With full funding, GAVI could introduce the vaccine in more than 40 countries by 2015. Between December 2010 and April 2011, GAVI launched pneumococcal vaccine in the following eight countries: Democratic Republic of Congo, Guyana, Honduras, Kenya, Mali, Nicaragua, Sierra Leone, and Yemen.
4. Meeting the funding challenge

The GAVI Alliance 2011 pledging conference for immunisation seeks to meet country demand for vaccines through a three-fold approach: 1) increased levels of donor contributions; 2) reductions in vaccine prices; and 3) increased co-financing from implementing countries. GAVI’s donors play a key leadership role in this process and all parties are called upon to demonstrate commitment to increasing access to new vaccines in poor countries.

Financial commitments are crucial to provide the necessary signals to shape vaccine markets. Donors may also use this occasion to inspire in countries the confidence to commit to long-term plans for immunisation, as well as give leadership to new and potential donors. GAVI’s comprehensive approach, led by donors, will ensure that financial resources are utilised efficiently to maximise impact.

GAVI is calling on existing donors to double or triple their commitments to reflect the two-fold increase in country demand. GAVI is also actively encouraging new donors to make pledges at the pledging conference. Public and private donors are urged to invest in GAVI through either direct contributions, and/or GAVI’s innovative financing mechanisms, including the International Finance Facility for Immunisation (IFFIm), and the Matching Fund for Immunisation (1+1+1).

Direct contributions from donors

Long-term commitments to GAVI will provide programme predictability to countries and enable GAVI to shape vaccine markets.

The GAVI Alliance is calling on donors to deliver multi-year pledges preferably for the full five-year period. The Secretariat will then work with donors, over the following months and years, to help deliver the pledges in the form of multi-year or annual grant agreements.

Pledges of support will be announced by existing donors at the conference, and new potential donors will also be invited to engage as the Alliance seeks broad global support. Countries and partners who joined the Muskoka initiative should be aware that, as agreed by the G8, funding to GAVI counts 100% towards meeting their Muskoka commitments.

The need for new IFFIm funding

IFFIm continues to be a key component in GAVI’s portfolio. It uniquely provides long-term visibility and predictability of funding and the flexibility to generate liquidity when most needed. Through these features, IFFIm has been instrumental in helping GAVI fund breakthrough vaccines quickly and securely.

However, IFFIm’s positive impact will decrease significantly over time unless there are new financial commitments made by donors. From 2006-2010, IFFIm provided more than 50% of GAVI’s overall funding. This percentage will decline to about 22% from 2011 to 2015, and to 7% from 2016 to 2020 if no new pledges are added. The GAVI Alliance is therefore calling on donors to consider sustained investments in IFFIm.

For some donors, IFFIm is a more fiscally efficient mechanism for supporting GAVI than direct contributions. IFFIm is an especially powerful tool for middle-income donors. Contributing through IFFIm would enable these countries to make a significant developmental impact starting
from a relatively modest cash commitment that grows over time. To maintain IFFIm’s credit standing, there is also a need to grow the AAA donor base in parallel with new countries joining the programme.

Results from a recent IFFIm evaluation are positive and very encouraging for IFFIm. According to the evaluation, IFFIm has significantly exceeded expectations in terms of efficiency, funding cost, investor reach and profile/reputation. One conclusion from the evaluation is that IFFIm should grow. Such growth would also help maintain IFFIm’s AAA credit rating and very efficient borrowing costs.

**Private sector support**

Support from the private sector is becoming a prominent component of the GAVI Alliance’s diversified financing strategy. The GAVI Campaign, a US-based non-profit organisation, leads this effort on behalf of the GAVI Alliance. Corporate partnerships, private philanthropy and campaign partnerships are innovative tools that can help to meet the funding challenge for 2011-2015.

As GAVI’s public-private partnerships evolve, an opportunity exists to leverage significant new funding by collaborating with high profile private sector actors. The pledging conference will also be an opportunity to recognise private donors’ contributions to the GAVI Alliance and the GAVI Campaign.

**Matching Fund for Immunisation: 1+1+1**

GAVI is launching a donor-backed matching fund that mobilises corporate partners and consumers (1+1+1). This represents a powerful strategy for attracting incremental funds to global health, building a diversified funding stream for GAVI, and bringing the development activities of the donor government closer to the taxpayer and business community.

The United Kingdom’s Department for International Development (DFID) is expected to announce participation in a 1+1+1 matching funds programme in the UK. GAVI encourages other donors to consider similar initiatives in their countries and would welcome an opportunity to work them in designing and implementing these projects.

**Liquidity Backstop Facility**

In addition to the preceding innovative finance projects, GAVI is in advanced discussions to establish a liquidity facility. This facility will enable GAVI to efficiently release approximately US$ 300 million from its cash reserves and mobilise these resources for vaccination programmes.
Annex 1:

**EXPENDITURES BY COMMITMENT LEVEL: 2011-2015 (projected)**
US$ millions, as of November 2010 (cash flow basis)

<table>
<thead>
<tr>
<th>Summary</th>
<th>Approved/Endorsed</th>
<th>Extensions</th>
<th>Balance of Demand</th>
<th>Total</th>
<th>% of direct programming</th>
<th>% of total expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine Programmes</td>
<td>2,171</td>
<td>956</td>
<td>2,172</td>
<td>5,299</td>
<td>86%</td>
<td>78%</td>
</tr>
<tr>
<td>Cash-based Programmes</td>
<td>255</td>
<td>0</td>
<td>596</td>
<td>852</td>
<td>14%</td>
<td>12%</td>
</tr>
<tr>
<td>Direct programmatic support</td>
<td>2,427</td>
<td>956</td>
<td>2,768</td>
<td>6,151</td>
<td>100%</td>
<td>90%</td>
</tr>
<tr>
<td>Business Plan</td>
<td>250</td>
<td>423</td>
<td>0</td>
<td>673</td>
<td>10%</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,677</strong></td>
<td><strong>1,379</strong></td>
<td><strong>2,768</strong></td>
<td><strong>6,824</strong></td>
<td></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

Note: At this time, the overall demand for 2011-15 is expected to remain close to this (November 2010) estimate of US$ 6.8 billion, with some fluctuations in individual components. Actual demand will evolve in the course of the five-year period. Arising from decisions of the Board in December 2010 regarding the resource envelope and eligibility for cash-based programmes, these programmes are likely to represent a share of programmatic expenditure in the range of 15%-25% in 2011-2015, rather than the 14% previously projected.

Annex 2:

**TIMING OF RESOURCE NEEDS: 2011-2015 (projected)**
US$ billions, as of November 2010 (cash flow basis)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outflows</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Existing programmes</td>
<td>0.97</td>
<td>0.96</td>
<td>0.83</td>
<td>0.72</td>
<td>0.57</td>
<td>4.1</td>
</tr>
<tr>
<td>Future programmes</td>
<td>0.19</td>
<td>0.49</td>
<td>0.64</td>
<td>0.64</td>
<td>0.80</td>
<td>2.8</td>
</tr>
<tr>
<td><strong>Total Outflows</strong></td>
<td><strong>1.16</strong></td>
<td><strong>1.46</strong></td>
<td><strong>1.47</strong></td>
<td><strong>1.37</strong></td>
<td><strong>1.37</strong></td>
<td><strong>6.8</strong></td>
</tr>
</tbody>
</table>

| **Assured Resources**  |      |      |      |      |      |         |
| Direct contributions - already committed | 0.11 | 0.15 | 0.11 | 0.13 | 0.05 | 0.6     |
| Expected proceeds from IFFIm (via GFA)     | 0.45 | 0.39 | 0.20 | 0.20 | 0.20 | 1.4     |
| Expected from AMC          | 0.13 | 0.28 | 0.25 | 0.12 | 0.04 | 0.8     |
| Drawdown of Cash & Investment Reserve | 0.24 | 0.03 | 0.08 | 0.02 | (0.03) | 0.3     |
| **Total Assured Resources** | **0.93** | **0.85** | **0.64** | **0.47** | **0.25** | **3.1** |

| **Resources Needed**     |      |      |      |      |      |         |
| Additional Resources Required / (surplus) | 0.24 | 0.61 | 0.83 | 0.90 | 1.11 | 3.7     |
| Additional Resources Required - Cumulative | | | | | | |
| Of which:                |      |      |      |      |      |         |
| - For existing programmes (cumulative) | 0.06 | 0.25 | 0.52 | 0.82 | 1.16 |         |
| - For future programmes (cumulative)    | 0.18 | 0.60 | 1.15 | 1.75 | 2.52 |         |